KWM
KNSA icon

Kingsview Wealth Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Kingsview Wealth Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,941
Closed -$386K – 1292
2025
Q3 		$386K Buy
+9,941
New +$323K 0.01% 884

Other funds holding KNSA

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Kingsview Wealth Management's KNSA Position: Q4 2025 in Review

Kingsview Wealth Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2025, closing a stake of 9,941 shares — an estimated $386K sold.

Kingsview Wealth Management first reported a position in KNSA in Q3 2025 and held it in 1 quarter. The position peaked at $386K in Q3 2025. 224 funds tracked by Wall St. Rank hold KNSA as of Q4 2025.

  • Kingsview Wealth Management reported no remaining Kiniksa Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Kingsview Wealth Management sold 9,941 Kiniksa Pharmaceuticals shares in Q4 2025, an estimated $386K.
  • Kingsview Wealth Management first reported a position in Kiniksa Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Kingsview Wealth Management's Kiniksa Pharmaceuticals position peaked at $386K in Q3 2025.
  • 224 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2025.

Based on Kingsview Wealth Management's 13F filing for Q4 2025, filed 9 Feb 2026.